BLSM NASDAQ
BlossomHill Therapeutics, Inc.
1W: -0.3%
1M: +1.6%
YTD: +23.1%
$19.69
+1.10 (+5.92%)
Weekly Expected Move ±16.7%
$13
$16
$20
$23
$26
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
2 bullish
0 neutral
2 bearish
Articles (7d)
4
Daily Sentiment (7 Days)
Articles (13)
BlossomHill Therapeutics (NASDAQ:BLSM) Shares Down 4.9% – Time to Sell?
BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up – Here’s Why
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
HC Wainwright Brokers Reduce Earnings Estimates for BLSM
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
BlossomHill closes up 18% on strongest day since August IPO
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
BlossomHill Therapeutics, Inc.’s Quiet Period Set To Expire on September 16th (NASDAQ:BLSM)
What is HC Wainwright’s Estimate for BLSM Q2 Earnings?
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
BlossomHill Therapeutics (NASDAQ:BLSM) Director Bihua Chen Purchases 312,500 Shares of Stock
Cancer drug developer BlossomHill slips after upsized IPO